Eli Lilly and Company announced on April 18, 2026, the acquisition of CrossBridge Bio, a biotechnology firm specializing in next-generation antibody-drug conjugates (ADCs). The deal is valued at approximately $300 million in upfront cash, with provisions for further payments based on the achievement of clinical and regulatory milestones. This acquisition is designed to bolster Lilly’s oncology division by incorporating CrossBridge’s proprietary linker-payload technology into its existing research and development pipeline.
CrossBridge Bio is known for its development of Dual-Payload ADCs, a technology that enables the delivery of two distinct cytotoxic agents through a single monoclonal antibody. This approach is engineered to target complex tumor microenvironments and mitigate the development of drug resistance in patients with solid tumors. The company’s lead asset, CBB-120, is a first-in-class ADC targeting a specific protein overexpressed in several types of cancer, including lung and breast cancers. The acquisition grants Lilly full rights to this candidate and the underlying platform technology.
Jacob Van Naarden, President of Loxo@Lilly, stated that the integration of CrossBridge Bio’s platform will allow the company to explore new combinations and therapeutic designs that were previously unattainable. Van Naarden emphasized that the site-specific conjugation methods developed by CrossBridge offer a more stable and predictable safety profile, which is a critical factor in the clinical success of ADC therapies. The scientific team from CrossBridge is expected to join the Loxo@Lilly unit to continue the development of the current pipeline and initiate new discovery programs.
The acquisition reflects a strategic effort by Eli Lilly to expand its footprint in the oncology sector, providing a counterbalance to its substantial market share in the GLP-1 and metabolic health segments. While Lilly’s recent financial performance has been heavily influenced by the success of tirzepatide, the company has consistently signaled its intent to remain a leader in targeted cancer treatments. This transaction follows a series of strategic moves in the ADC and radiopharmaceutical space, including the previous acquisitions of Point Biopharma and Mablink Bioscience.
The deal is subject to standard closing conditions and regulatory reviews, including oversight by the Federal Trade Commission. Eli Lilly and CrossBridge Bio anticipate the transaction will be finalized by the end of the second quarter of 2026. Following the close, CrossBridge’s operations in Houston will be maintained as a specialized research hub within the Lilly oncology network. No immediate changes to Lilly’s 2026 financial guidance were announced in conjunction with the deal.